Patent ID: 7879893

Claim:
A zinc-binding ligand of the following formula (III) A-B-C-D-X (III) wherein: A is a chemical group of the following formula which reversibly binds to a His B10 Zn 2+ site of an insulin hexamer; wherein A 1 is a valence bond; AR 1 is the group where C1 is attached to the nitrogen; C 1 is CH2; AR 2 is phenyl; B is a linker selected from the group consisting of A valence bond and A chemical group G B of the formula —B 1 —B 2 —C(O)—, —B 1 —B 2 —SO 2 —, —B 1 —B 2 —CH 2 —, or —B 1 —B 2 —NH—; wherein B 1 is a valence bond, —O—, —S—, or —NR 6 —, B 2 is a valence bond, C 1 -C 18 -alkylene, C 2 -C 18 -alkenylene, C 2 -C 18 -alkynylene, arylene, heteroarylene, —C 1 -C 18 -alkyl-aryl-, —C 2 -C 18 -alkenyl-aryl-, —C 2 -C 18 -alkynyl-aryl-, —C(═O)—C 1 -C 18 -alkyl-C(═O)—, —C(═O)—C 1 -C 18 -alkenyl-C(═O)—, —C(═O)—C 1 -C 18 -alkyl-O—C 1 -C 18 -alkyl-C(═O)—, —C(═O)—C 1 -C 18 -alkyl-S—C 1 -C 18 -alkyl-C(═O)—, —C(═O)—C 1 -C 18 -alkyl-NR 6 —C 1 -C 18 -alkyl-C(═O)—, —C(═O)-aryl-C(═O)—, —C(═O)-heteroaryl-C(═O)—; wherein the alkylene, alkenylene, and alkynylene moieties are optionally substituted with —CN, —CF 3 , —OCF 3 , —OR 6 , or —NR 6 R 7 and the arylene and heteroarylene moieties are optionally substituted with halogen, —C(O)OR 6 , —C(O)H, OCOR 6 , —SO 2 , —CN, —CF 3 , —OCF 3 , —NO 2 , —OR 6 , —NR 6 R 7 , C 1 -C 18 -alkyl, or C 1 -C 18 -alkanoyl; R 6 and R 7 are independently H, C 1 -C 4 -alkyl; C is a fragment consisting of 0 to 5 neutral amino acids, wherein the individual neutral amino acids are the same or different D is a fragment consisting of 1 to 20 basic amino acids independently selected from the group consisting of Lys and Arg or D-isomers thereof; and X is —OH, —NH 2 or a diamino group, or a salt thereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or tautomeric forms thereof.